

• •



-

-

•

• •

-



.....2

.....3

.....5

.....5

-10.....7

.....7

.....7

.....8

.....9

.....9

.....10

.....10

.....11

.....11

.....12

.....12

.....13

.....13

.....14

.....15

.....15

.....18

.....20

.....22

XVIII
2015 .

«

» 15

: (. , -
 . ” . ” . ” . ” .),
(. ” . ” . ” . ” .), « . . .
 .), » (. ”
 . .) (.)
 / ,
 .
 ,
 /
 .
 /
 ,
 EMBASE MEDLINE. 5 .
 ,
 .
 (. 1).
 1.

1			

<p>1</p> <p>,</p>	<p>,</p>	<p>(</p> <p>),</p> <p>.</p> <p>(</p> <p>),</p> <p>.</p>	<p>,</p>
<p>1</p> <p>,</p>	<p>,</p> <p>,</p>	<p>,</p> <p>,</p> <p>,</p> <p>.</p> <p>.</p>	<p>,</p>
<p>2</p> <p>,</p>		<p>,</p> <p>.</p>	<p>.</p> <p>(</p> <p>),</p> <p>.</p>
<p>2</p> <p>,</p>	<p>,</p> <p>.</p>	<p>(</p> <p>),</p> <p>-</p> <p>.</p> <p>(</p> <p>),</p> <p>.</p>	<p>.</p>

2			
---	--	--	--

, :
 • - ;
 • .
 ,
 , ,
 . - ,
 .
 ,
 .
 -
 -
 , , ,
 , . ,
 , , ,
 , , ,
 , , ,
 .

2015

() -

()

()

()

Reoviridae,

Sedoreovirinae,

Rotavirus,

(VP),

VP1, VP2, VP3, VP4, VP6 VP7.

VP6 (viral protein)

7

: A, B, C, D, E, F, G.

- VP7 (G-) VP4 (-), -

(G),

98%

() . 90% 5
- G1P[8], G2P[4], G3P[8], G4P[8], G9P[8].

30 (60 , - 10
) ,
9 / 2 15 .
7 , - 5 30 , - 12 45
, - 10 , - 16 .
, , , -
, , .
(
3-9). (,)

10 , 80⁰ - 1 . 70⁰

-10

A08.0 -

5 -

() ,
() 2008 . 453 .

, 35
 , 40% 5
 (1986–2000 .) [1]. ,
 5–27%
 , 48–69%
 .
 , , ,
 c
 (5–10%) , .
 , , - ,
 2–5 (2011 .).
 6–24 (65–85%),
 .
 43% 15 Vesikari, 7%
 , 3% - ; 27%
 .
 3–4 .
 ,
 10 (3,2 100 000 1993 . 74,95 – 2014 .).
 , 2005–2007 . 8
 «
 », ,
 43% 5 , .
 - ,
 .
 2014 . 1 1180,07 100 .,
 1-2 – 1351,37 100 . , 1

20,6%, 1-2 – 44,7%.
: 31,08 100 . -
3145,66 100 . , , , ,
. , ,
1-2 9 000 100 . .
2012 . , , ,
« - , ,
» , ,
31% ,
75% [4].
G[P]
2011–2013 . ,
. .
: G4[P]8 - 42,5%, G1[P]8 - 19,7%, G3[P]8 – 15,2%, G2[P]4 –
7,8% G9[P]8 – 4,9%.
, (,
), (,),
, . . [5, 6]. ,
1 17 394 [7].
95% ,
, 45,31 . ., 18,98 . . – ,
26,33 . . – , [8].

1 3 .

(, ,),

20-30 .

[9].

5-7 .

21.03.2014), (125

(RV1) ()
 (RV5) (,).
 -
 (; 2 ; -001865). 1 (2)
 :
 : G1 - $2,2 \cdot 10^6$ ¹,
 G2 - $2,8 \cdot 10^6$, G3 - $2,2 \cdot 10^6$, G4 - 2,0
 10^6 , P1A - $2,3 \cdot 10^6$ [8].
 : - 1080 , 2,75 , 127 ,
 29,8 , -80, .
 - (),
 ().
 VP7
 (G1, G2, G3 G4) VP4 (P7[5])
 (VP4).
 VP4 (P1A[8])
 VP7 (G6)

¹ -

,
 - G1, G2, G3, G4, G,
 1 [8] (, G9), -
 92,5-100%
 IgA
 ,
 ,
 , 3
 100%,
 - 59%.
 96 28% [10].
 2008 2009 .
 44% 58% -
 89% 89%.
 37% 48%,
 - 9% 12% . 5
 88%, «
 » [11].
 / , 3 100%
 . 2 81%, 1 - 69%
 [12].
 2007-2009 .
 64 855 \$278 . [13].
 100%, - 68-87%. 2 81-
 94%,
 - 96%. , 2
 33%,

- - 36%.

57%,

- 62%.

3 [14].

2-4

12

[15, 16].

[17, 18].

2006-2007

50%

2-4-

[19].

6 32

•

•

•

•

•

/

•

•

2

6

2 (1)

(!).

(2)

1.2 10¹²

2-8 °C

24

4 10

6 12

6

3-

32

6

32

1)

: 1-

2

4,5 6 .)

, 2- 3- - 3 4,5 . (

2)

3-4,5-6 .

30

25

2

48-72

42 (1,5)

()

/ - .

()

[13].

III

(The Rotavirus Efficacy and Safety Trial -

REST).

68 038
 42
 (38⁰ 20,95%), (17,6%)
 (10,1%).

(),
 , ()
 , , ”)
 . (.)

3.

(1/10)	(1/100, <1/10)	(1/1000, <1/100)	(1/10000, <1/1000)	
,		,	,	,
		,	,	,
		,		

4

6-12

[1].

(, , ,)

, 1-2 100 000 .

- (

) .

, , ,

, .

8,9% , - 0% 0,3% .

, , , ,

, .

.

(

),

, 3.1.1.2957-11 « ,

».

-

,

:

•

;

•

7 ,

()

;

•

,

,

7 :

,

,

•

(

,

,

.)

;

•

,

,

;

•

(

.)

,

.

,

;

•

(

)

7

.

,

(

,

,

,

).

,

.

13. Cortes JE, Curns AT, Tate JE. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. *N Engl J Med*. 2011 Sep 22;365(12):1108-17. doi: 10.1056/NEJMoa1000446.
14. Vesikary T, Van Damme P, Giaquinto C, et al. European Society for prdiatric infectious diseases consensus recommendations for rotavirus vaccination in Europe. *The Pediatr. Inf. Dis, J* 2015;14 (6):635-643.
15. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity—United States, November 2007–May 2008. *MMWR Morb Mortal Wkly Rep* 2008; 57:697-700; PMID: 18583958. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5725a6.htm>.
16. Centers for Disease Control and Prevention (CDC). Reduction in rotavirus after vaccine introduction— United States 2000–2009. *MMWR Morb Mortal Wkly Rep* 2009; 58:1146-9; PMID: 19847149. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5841a2.htm>.
17. Cortese M, Tate J, Simonsen L, Edelman L, Parashar U. Reduction in gastroenteritis in children and correlation with rotavirus vaccine uptake from a national medical claims database. 47th Annual Meeting of the Infections Diseases Society of America (IDSA). 29 October–1 November 2009; Philadelphia, PA USA.
18. Lieberman JM, Huang X, Koski E, Kaufman H, Furlanetto R, Hurwitz H, et al. Decline in rotavirus cases in the US after licensure of a live, oral rotavirus vaccine. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25–28 October 2008; Washington, DC USA.
19. Lambert SB, Faux CE, Hall L, Birrell FA, Peterson KV, Selvey CE, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Erratum in: *Med J Aust*, 2010; 192:525. *Med J Aust*, 2009; 191:157-60; PMID: 19645646.
20. 3.1.1.2957-11 « , ».

-
-
-
-
-
-
-
-